VEGFA and neoplasm: Therapeutically, inhibitors targeting the VEGF/PDGF axis are widely used in anti-angiogenic cancer treatment; however, resistance frequently develops, often linked to tumor metabolic adaptation under anaerobic conditions [68, 69].